FI3370760T3 - Plasminogeenivajauksen plasminogeenikorvaushoito - Google Patents

Plasminogeenivajauksen plasminogeenikorvaushoito

Info

Publication number
FI3370760T3
FI3370760T3 FIEP16861682.9T FI16861682T FI3370760T3 FI 3370760 T3 FI3370760 T3 FI 3370760T3 FI 16861682 T FI16861682 T FI 16861682T FI 3370760 T3 FI3370760 T3 FI 3370760T3
Authority
FI
Finland
Prior art keywords
plasminogen
glu
deficiency
use according
subject
Prior art date
Application number
FIEP16861682.9T
Other languages
English (en)
Finnish (fi)
Inventor
Martin Robitaille
Karen Thibaudeau
Pierre Laurin
Stacy Plum
Original Assignee
Kedrion Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kedrion Biopharma Inc filed Critical Kedrion Biopharma Inc
Application granted granted Critical
Publication of FI3370760T3 publication Critical patent/FI3370760T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FIEP16861682.9T 2015-11-03 2016-11-03 Plasminogeenivajauksen plasminogeenikorvaushoito FI3370760T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562250235P 2015-11-03 2015-11-03
PCT/IB2016/001599 WO2017077380A1 (en) 2015-11-03 2016-11-03 Plasminogen replacement therapy for plasminogen-deficiency

Publications (1)

Publication Number Publication Date
FI3370760T3 true FI3370760T3 (fi) 2025-12-05

Family

ID=58661917

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP16861682.9T FI3370760T3 (fi) 2015-11-03 2016-11-03 Plasminogeenivajauksen plasminogeenikorvaushoito

Country Status (16)

Country Link
US (1) US11291711B2 (enExample)
EP (1) EP3370760B1 (enExample)
JP (1) JP6878423B2 (enExample)
KR (1) KR102821400B1 (enExample)
CN (1) CN108289935A (enExample)
AU (1) AU2016347863B2 (enExample)
BR (1) BR112018008965A8 (enExample)
CA (1) CA3002915C (enExample)
FI (1) FI3370760T3 (enExample)
IL (1) IL258913B (enExample)
MX (1) MX2018005588A (enExample)
MY (1) MY199581A (enExample)
RU (1) RU2736831C2 (enExample)
TW (1) TWI801331B (enExample)
WO (1) WO2017077380A1 (enExample)
ZA (1) ZA201802820B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201722464A (zh) * 2015-11-10 2017-07-01 波麥堤克生化科學有限公司 用於傷口癒合之纖維蛋白溶酶原給藥方案
DK3395354T3 (da) 2015-12-18 2024-06-03 Talengen Int Ltd Plasminogen til anvendelse i behandling af diabetisk nefropati
EP3395353B1 (en) 2015-12-18 2024-03-06 Talengen International Limited Plasminogen for use in treating or preventing diabetes mellitus nerve injury
TWI653982B (zh) * 2015-12-18 2019-03-21 大陸商深圳瑞健生命科學研究院有限公司 Method for preventing or treating acute and chronic thrombosis
ES2961967T3 (es) 2015-12-18 2024-03-14 Talengen Int Ltd Plasminógeno para su uso en el tratamiento de la angiocardiopatía diabética
WO2017161354A1 (en) * 2016-03-17 2017-09-21 Vanderbilt University Enhancing plasmin activity to prevent soft tissue calcification
CN110167583A (zh) * 2016-12-15 2019-08-23 泰伦基国际有限公司 一种治疗冠状动脉粥样硬化及其并发症的方法
JP7175270B2 (ja) 2016-12-15 2022-11-18 タレンゲン インターナショナル リミテッド グルカゴン、インスリンを正常なバランスに戻らせる方法
TW201822790A (zh) 2016-12-15 2018-07-01 大陸商深圳瑞健生命科學研究院有限公司 一種預防和治療皮膚纖維化的方法
CN110114081A (zh) 2016-12-15 2019-08-09 泰伦基国际有限公司 一种改善心脏病变的方法
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
CN109125715A (zh) * 2017-06-19 2019-01-04 深圳瑞健生命科学研究院有限公司 一种调控glp-1/glp-1r的方法和药物
DK3643321T3 (da) * 2017-06-19 2025-08-18 Talengen Int Ltd Plasminogen til anvendelse i behandling af parkinsons og alzheimers sygdom
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
CN113597313A (zh) * 2019-01-24 2021-11-02 先觉药业咨询公司 用于治疗和预防微血栓形成的纤溶酶原
EP3812772B1 (en) * 2019-10-24 2025-02-19 Hôpitaux Universitaires de Strasbourg (HUS) Method for diagnosing fibrinolytic insufficiency related to neutrophil extracellular traps
US12497607B2 (en) * 2020-04-23 2025-12-16 Previpharma Consulting Gmbh Plasminogen for use in treating and preventing lung dysfunction
CN114354929A (zh) * 2022-01-07 2022-04-15 南京鼓楼医院 一种用于监测人体纤溶状态的试剂盒及应用
WO2025049724A1 (en) * 2023-08-29 2025-03-06 Board Of Regents Of The University Of Nebraska Compositions and methods for treating pleural space infections and hemothorax

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2254316B1 (enExample) * 1973-12-18 1977-04-22 Choay Sa
JP2764264B2 (ja) * 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
AT402367B (de) * 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen
AU4661493A (en) * 1992-07-01 1994-01-31 Beth Israel Hospital Boston Enhancement of thrombolytic therapy with deglycosylated plasminogen
EP0682700A4 (en) * 1993-02-05 1997-05-28 Vascular Lab USE OF UROKINASE-LIKE PLASMINOGEN ACTIVATORS IN THE INTERIOR OF PLATES FOR THE LONG-TERM INHIBITION OF THROMBOSE.
US20030224516A1 (en) * 2002-06-03 2003-12-04 Isis Pharmaceuticals Inc. Antisense modulation of prox-1 expression
US7067492B2 (en) * 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
US20050271636A1 (en) * 2002-08-09 2005-12-08 St. Jude Children's Research Hospital, Inc. Diagnostic and therapeutic uses for prox 1
GB0509438D0 (en) * 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
DK2056864T3 (en) * 2006-08-28 2014-03-10 Omnio Healer Ab CANDIDATES AGAINST INFECTION
WO2008027000A2 (en) * 2006-08-28 2008-03-06 Omnio Healer Ab Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
WO2011004011A1 (en) * 2009-07-10 2011-01-13 Thrombogenics Nv Variants of plasminogen and plasmin
JP6343147B2 (ja) * 2010-08-30 2018-06-13 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 狭窄病変および血栓溶解療法のための剪断による制御放出
PT3233111T (pt) 2014-12-19 2024-10-10 Kedrion Biopharma Inc Composição farmacêutica que compreende éniplasminogénio e seus usos
CN108463240A (zh) * 2015-12-18 2018-08-28 泰伦基国际有限公司 一种预防或治疗糖尿病性视网膜病变的方法

Also Published As

Publication number Publication date
MX2018005588A (es) 2018-11-09
RU2736831C2 (ru) 2020-11-20
CA3002915A1 (en) 2017-05-11
EP3370760B1 (en) 2025-10-01
AU2016347863B2 (en) 2023-11-09
KR102821400B1 (ko) 2025-06-18
WO2017077380A1 (en) 2017-05-11
AU2016347863A1 (en) 2018-06-07
JP2018533589A (ja) 2018-11-15
NZ742657A (en) 2024-04-26
CA3002915C (en) 2024-01-16
BR112018008965A8 (pt) 2019-02-26
IL258913A (en) 2018-06-28
RU2018120182A3 (enExample) 2020-04-27
US20190231854A1 (en) 2019-08-01
JP6878423B2 (ja) 2021-05-26
BR112018008965A2 (pt) 2018-11-21
IL258913B (en) 2021-12-01
TW201722463A (zh) 2017-07-01
TWI801331B (zh) 2023-05-11
EP3370760A4 (en) 2019-06-26
EP3370760A1 (en) 2018-09-12
KR20180083348A (ko) 2018-07-20
US11291711B2 (en) 2022-04-05
ZA201802820B (en) 2019-07-31
MY199581A (en) 2023-11-07
CN108289935A (zh) 2018-07-17
RU2018120182A (ru) 2019-12-04

Similar Documents

Publication Publication Date Title
FI3370760T3 (fi) Plasminogeenivajauksen plasminogeenikorvaushoito
WO2020121310A3 (en) Method of treating cancer with a cancer therapy in combination with another therapeutic agent
MX389927B (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
MX2022015499A (es) Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.
MX2021002321A (es) Nuevos metodos.
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
EP4269439A3 (en) Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
SG10201811185YA (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
MY174018A (en) Heterocyclic derivates
MX2015012520A (es) Ensayos y metodos para seleccionar un regimen de tratamiento para un sujeto con depresion.
WO2006102596A3 (en) Dosage regimen for the treatment of a traumatic brain injury with progesterone
SG10201903112WA (en) Treatment of cancer using coenzyme q10 combination therapies
WO2017042633A3 (en) Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
HRP20211824T1 (hr) Modulatori aktivnosti komplementa
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2019004602A (es) Agentes anti-proliferativos para tratar pah.
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX2014015096A (es) Alimento para crustaceos.
MX2016011002A (es) Tratamiento de angioedema hereditario con inhibidor c1.
Polak Clomipramine/paroxetine
UA116484U (uk) Cпосіб лікування артеріальної гіпертензії з метаболічним синдромом
Knight Azathioprine/methotrexate/mycophenolate mofetil